United Therapeutics (NASDAQ:UTHR) CEO Sells $5,700,855.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $600.09, for a total value of $5,700,855.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $194,694,999.87. This represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Price Performance

UTHR stock opened at $608.49 on Thursday. United Therapeutics Corporation has a one year low of $432.53 and a one year high of $614.23. The stock has a market cap of $26.10 billion, a price-to-earnings ratio of 21.77, a price-to-earnings-growth ratio of 4.35 and a beta of 0.49. The company has a fifty day moving average price of $532.33 and a two-hundred day moving average price of $532.45.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). The company had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the previous year, the company earned $7.16 earnings per share. Research analysts anticipate that United Therapeutics Corporation will post 26.09 EPS for the current fiscal year.

United Therapeutics declared that its Board of Directors has approved a share buyback plan on Thursday, October 22nd that authorizes the company to buy back $2 billion in outstanding shares. This repurchase authorization authorizes the biotechnology company to reacquire up to 8.3% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently bought and sold shares of UTHR. BlackRock Inc. acquired a new stake in shares of United Therapeutics during the 2nd quarter worth $2,868,735,000. Jupiter Topco LLC acquired a new position in United Therapeutics in the second quarter valued at about $450,140,000. Bank of New York Mellon Corp acquired a new position in United Therapeutics in the second quarter valued at about $159,522,000. Caisse de depot et placement du Quebec acquired a new position in United Therapeutics in the second quarter valued at about $154,304,000. Finally, Legal & General Group Plc bought a new stake in United Therapeutics during the second quarter worth about $112,209,000. 94.08% of the stock is owned by institutional investors.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 4.1% year over year to $832.5 million, beating analyst expectations of about $781 million. Management said the company is entering a period of stronger growth and advancing new therapies. United Therapeutics Q3 2026 results
• Positive Sentiment: BTIG raised its price target to $768 from $728 and maintained a Buy rating, signaling continued analyst confidence in the shares. BTIG Research ratings
• Positive Sentiment: The company announced a buyout of Pfizer’s royalty rights tied to ralinepag, a lung-disease therapy. Ending those royalties could improve the drug’s future economics, though the announcement details provided no financial terms. Ralinepag royalty buydown announcement
• Negative Sentiment: Adjusted earnings were a weak spot: EPS of $5.71 missed the approximately $6.01 consensus and fell from $7.16 a year earlier. Reports also noted lower net income. Q3 earnings miss
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares, reducing her direct holding by 2.84%. She retained 324,443 shares; the sale may draw investor attention but does not by itself establish a change in the company’s outlook. United Therapeutics insider trades

Analysts Set New Price Targets

Several research analysts have weighed in on UTHR shares. JPMorgan Chase & Co. lowered their price target on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating on the stock in a report on Wednesday, October 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $850.00 target price on shares of United Therapeutics in a research report on Monday, October 26th. Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Jefferies Financial Group reiterated a “buy” rating and set a $728.00 target price on shares of United Therapeutics in a research note on Wednesday, October 14th. Finally, The Goldman Sachs Group reissued a “sell” rating and set a $368.00 price target on shares of United Therapeutics in a report on Thursday, October 15th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $674.00.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.